Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 12/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962855 | 0.81 | PNP (1.00) | PNPKDM4EFGFR1FGFR2 | |
| Hydrochloric Acid SCHEMBL17186372 | 0.80 | PNP (0.97) | PNPKDM4EFGFR1FGFR2 | |
| SCHEMBL4963414 | 0.80 | PNP (0.64) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL9960811 | 0.79 | PNP (0.71) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL4967481 | 0.78 | PNP (0.65) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3310268 | 0.77 | PNP (0.75) | PNPFGFR1FGFR2 | |
| SCHEMBL5935062 | 0.75 | PNP (0.70) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2097436 | 0.75 | FGFR1 (0.52) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3300185 | 0.74 | PNP (0.64) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL9434519 | 0.74 | PNP (0.64) | PNPFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| CN-1948313-A | Preparation method of tiemoazoleamine-8-carboxylic acid water soluble derivative, anticancer activity and application in preparing anticancer medicine | TIANJIN BEIFANG SCIENCE AND TE (CN) | 2007-04-18 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | claimed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | claimed |
| EP-4319773-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230339991-A1 | HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023150393-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | ENSOMA, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | disclosed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2005068465-A1 | 2-AMINO-O4-SUBSTITUTED PTERIDINES AND THEIR USE AS INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1546370-A1 | PROTEIN LABELLING WITH O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031404-A1 | PROTEIN LABELLING WITH O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-04-15 | — | — | WO | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| US-6096724-A | O(6)-ALKYLGUANINE-DNA ALKYLTRANSFERASE (ATASE) ENZYME INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | PNP 1267/4885KDM4E 1149/4885MEN1 3755/4885 |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | MGMT, NNMT, GNMT | PNP 1264/4885KDM4E 618/4885MEN1 3310/4885 |
| US-20230339991-A1 | HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF | HIF1AN, HIF1A, MGMT | PNP 146/4885KDM4E 901/4885MEN1 2607/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PNP 569/4885KDM4E 2277/4885MEN1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.